The PPARα inhibitor antagonized the beneficial effect of BO, confirming previous evidence obtained in the kidneys.25 The greater efficacy of fenofibrate versus BO on stroke protection may be explained by the additional molecular and pharmacological properties of the drug. The gene discussed is PPARA; the disease is Stroke.